Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353906 | 1.00 | ADRB2 (0.39) | ADRB2ALOX5APLMNAPRNPMAPT | |
| SCHEMBL5353356 | 0.89 | ADRB2 (0.41) | ADRB2LMNAADRB3 | |
| SCHEMBL6705286 | 0.87 | ADRB2 (0.43) | ADRB2TDP1ADRB3 | |
| SCHEMBL5349538 | 0.86 | ABCB1 (0.39) | ADRB2 | |
| SCHEMBL5353704 | 0.86 | ADRB2 (0.51) | ADRB2ADRB3 | |
| SCHEMBL10753050 | 0.85 | HMOX1 (0.40) | ADRB2 | |
| SCHEMBL5354273 | 0.84 | ADRB2 (0.44) | ADRB2ADRB3 | |
| SCHEMBL5347604 | 0.84 | ADRB2 (0.44) | ADRB2ADRB3 | |
| SCHEMBL6705283 | 0.78 | ADRB2 (0.50) | ADRB2LMNAADRB3 | |
| SCHEMBL4014708 | 0.77 | ADRB2 (0.50) | ADRB2LMNATDP1CCR5ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214698-B2 | Beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-08 | — | — | US | disclosed |
| US-20060173061-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-03 | — | — | US | disclosed |
| EP-1558583-A1 | NOVEL PHENYLETHANOLAMINE DERIVATIVES AND THE USE OF THE SAME AS BETA-3-AGONISTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040127733-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-01 | — | — | US | disclosed |
| WO-2004039784-A1 | NOVEL PHENYLETHANOLAMINE DERIVATIVES AND THE USE OF THE SAME AS BETA-3-AGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173061-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | ADRB1, ADRB2, ADRA1A | ADRB2 2/4885ALOX5AP 1388/4885LMNA 858/4885 |
| US-20040127733-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | ADRB1, ADRA1A, ADRA1D | ADRB2 5/4885ALOX5AP 1428/4885LMNA 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.